

Contents

Part A

Chapter 1	Cytochrome P450 Structure and Function: An Evolutionary Perspective	
	<i>David F.V. Lewis and Yuko Ito</i>	
1.1	Introduction	4
1.2	Evolutionary Aspects	7
1.3	Binding Functions of P450	11
1.4	Substrate Binding and Selectivity	15
1.5	P450 Catalysis	24
1.6	Structural Modelling of P450s	29
	1.6.1 Molecular Modelling and Dynamics of P450s	30
	1.6.2 Lipophilicity Relationships in P450 Substrate Binding and Selectivity	35
1.7	Conclusions	37
	Abbreviations	38
	Acknowledgements	39
	References	39
Chapter 2	Generation of Reactive Intermediates by Cytochromes P450	
	<i>Hermann M. Bolt and Peter H. Roos</i>	
2.1	Introduction	47
2.2	Determinants of Biologically Reactive Metabolites	49
	2.2.1 General Principles of Biological Reactivity	49
	2.2.2 Application to Aliphatic Epoxides	50
	2.2.3 Structure-Genotoxicity Relationship: Aliphatic Olefins and Their Epoxides	52

Issues in Toxicology

Cytochromes P450: Role in the Metabolism and Toxicity of Drugs and other Xenobiotics

Edited by Costas Ioannides

© Royal Society of Chemistry, 2008

2.3	Suicide Substrates for CYP Enzymes	55
2.4	Formation of Reactive Intermediates: Toxicological Determinants	57
2.4.1	Bioactivation, Organotropism and Species Differences of <i>N</i> -Nitrosamines	57
2.4.2	Endogenous Compounds: Biological Activation of Oestrogens	59
2.5	Application to Polycyclic Aromatic Hydrocarbons	63
2.5.1	Dihydrodiolepoxides (DDE)	66
2.5.2	Radical Cations	72
2.5.3	Quinone Pathway	74
2.5.4	'Polar Metabolites'	75
2.5.5	Specific PAHs	78
2.5.6	Specific CYPs	82
2.5.7	Specific Sites: CYP Profiles, Subcellular CYP-localisations	84
2.5.8	General Conclusions Regarding PAH-derived Reactive Metabolites	85
2.6	Final Remarks	86
	References	86

Part B

Chapter 3 The CYP1A Subfamily

Bhagavatula Moorthy

3.1	Introduction	98
3.2	Human CYP1A Enzymes and Their Role in Drug Metabolism	99
3.3	Ontogenic Expression of CYP1A Enzymes	101
3.4	Role of CYP1A1 Enzymes in Human Carcinogenesis	102
3.4.1	Human Exposure to PAHs	102
3.4.2	Role of CYP1A Enzymes in PAH Metabolism	103
3.4.3	Genetic Polymorphisms of CYP1A and Human Cancers	103
3.5	Molecular Mechanisms of CYP1A Induction	104
3.6	Persistent Induction of CYP1A1	106
3.6.1	AHR Contributes to Sustained Induction of CYP1A1 by Persistent Chemicals	106
3.6.2	MC Elicits Sustained Induction of CYP1A1 by Mechanisms Other than Persistence of the Parent Compound	106
3.6.3	Persistent CYP1A1 Induction in Extrahepatic Tissues	107

3.6.4	Sustained CYP1A1 Induction in Humanised Transgenic Mouse	108
3.7	Relevance of CYP1A1 Induction to Tumourigenesis	108
3.8	CYP1A, Ki-ras Mutations, and Lung Tumourigenesis	109
3.9	Mechanisms of CYP1A2 Induction	110
3.10	CYP1A in Laboratory Animals	110
3.10.1	Species Differences	110
3.10.2	Tissue-specific Expression	111
3.11	The <i>cyp1a</i> Knockout Mouse Models	112
3.12	Studies with Humanised Mice	114
3.13	Role of CYP1A Enzymes in the Metabolism of Endogenous Substances	114
3.13.1	Role of CYP1A Enzymes in ROS Metabolism	114
3.13.2	Modulation of ROS by CYP1A Enzymes	115
3.13.3	CYP-dependent Arachidonic Acid (AA) Metabolism	115
3.13.4	AA is an Endogenous CYP1A Substrate in Humans	116
3.13.5	Other Endogenous CYP1A Substrates	116
3.13.6	Role of CYP1A Enzymes in Hyperoxic Lung Injury	118
3.13.7	F ₂ Isoprostanes, Isofurans, and Hyperoxic Lung Injury	119
3.14	Protective Effects of CYP1A Induction	120
3.14.1	Mechanisms for Beneficial Effects of CYP1A Enzymes	121
3.15	Conclusions	122
	Acknowledgements	123
	References	123

Chapter 4 The CYP1B Subfamily

Morag C.E. McFadyen and Graeme I. Murray

4.1	Introduction	137
4.2	Mechanisms of Regulation of CYP1B1	137
4.2.1	Transcriptional Regulation of CYP1B1	138
4.3	Tissue Specific Expression of CYP1B1	140
4.3.1	CYP1B1 and Disease	140
4.4	Role of CYP1B1 in Drug Metabolism	141
4.4.1	CYP1B1 Metabolism of Specific Drugs	143
4.4.2	CYP1B1 Activated Prodrugs in Development	143
4.5	Inhibitors of CYP1B1	144
4.6	Drug Metabolism and Pharmacogenetics of CYP1B1	144
4.7	Conclusions	145
	References	146

Chapter 5 The CYP2A Subfamily*Hannu Raunio, Jukka Hakkola and Olavi Pelkonen*

5.1	Introduction	151
5.2	Species and Tissue Distribution	151
5.3	Substrate Specificity	153
5.4	Developmental and Tissue Selective Regulation and Effect of Physiological and Pathological Factors	154
5.4.1	Ontogenic Expression	154
5.4.2	Regulation of Tissue Expression	154
5.4.3	Regulation by Physiological Factors	155
5.4.4	Impact of Disease on CYP2A Liver Expression	156
5.5	Regulation by Xenobiotics	156
5.6	Structure of the Human CYP2A6 Enzyme	158
5.6.1	Molecular Modelling	158
5.6.2	Mutagenesis Studies	159
5.7	Pharmacogenetics of Human CYP2A Genes	159
5.8	Role in Drug Metabolism	160
5.8.1	Drug Substrates	160
5.8.2	Inhibitors	161
5.9	Role in Xenobiotic Toxicity	162
5.9.1	Toxic Substrates	162
5.9.2	Nicotine	162
5.9.3	<i>N</i> -Nitrosamines	165
5.10	CYP2A6 Polymorphism and Cancer	167
5.10.1	Lung Cancer	167
5.10.2	Other Cancers	168
5.11	Implications for Risk Assessment – Coumarin	168
5.12	Conclusions	170
	References	171

Chapter 6 The CYP2B Subfamily*Laurent Corcos and François Berthou*

6.1	Introduction	179
6.2	The CYP2B Gene Family	180
6.2.1	Substrates and Inhibitors	181
6.3	Regulation of CYP2B Gene Expression	184
6.3.1	Species and Tissue Sites in Mammals	184
6.3.2	Sex-dependent Regulation of CYP2B Expression	185
6.3.3	Hormonal Regulation	185
6.3.4	The Influence of Pathology and Inflammation	186
6.3.5	Model Systems to Investigate Enzyme Activity and Gene Regulation	186
6.4	Genetic Polymorphism and Splice Variants	188

<i>Contents</i>	xiii
6.5 Suicide-based Strategies in Cancer Therapy Protocols	190
6.6 Biochemistry of CYP2B Enzymes	192
6.6.1 Structural Features of CYP2B Family Members	192
6.7 Conclusions and Future Prospects	194
Acknowledgements	195
References	195
Chapter 7 The CYP2C Subfamily	
<i>Stephen S. Ferguson, Karen Black and Jonathan P. Jackson</i>	
7.1 Introduction to the CYP2C Subfamily, Importance and Scope	201
7.2 CYP2C Chromosomal Comparisons: Human, Mouse and Rat	202
7.3 Contribution of CYP2C to Drug and Xenobiotic Metabolism	205
7.3.1 Metabolism Catalysed by CYP2C8	205
7.3.2 Metabolism Catalysed by CYP2C9	208
7.3.3 Metabolism Catalysed by CYP2C19	210
7.4 Pharmacogenetics of CYP2C	211
7.4.1 CYP2C8 Pharmacogenetics	212
7.4.2 CYP2C9 Pharmacogenetics	212
7.4.3 CYP2C19 Pharmacogenetics	218
7.4.4 Perspective on Pharmacogenetics of CYP2Cs	219
7.5 Drug-Drug Interactions Involving CYP2C	220
7.5.1 Drug-Drug Interactions - Inhibition	220
7.5.2 Drug-Drug Interactions - Induction and Suppression	226
7.6 Conclusions and Summary	233
References	233
Chapter 8 The CYP2D Subfamily	
<i>Ulrich M. Zanger</i>	
8.1 Introduction and Molecular Genetics of the <i>CYP2D</i> Subfamily	242
8.2 Catalytic Properties and Structure of CYP2D Enzymes	243
8.2.1 Role in Drug and Xenobiotic Metabolism	244
8.2.2 Potential for Drug-Drug Interactions	247
8.2.3 Role in Endogenous Biotransformation	247
8.3 Species Differences in <i>CYP2D</i> Molecular Genetics, Expression and Function	248
8.3.1 CYP2D in Nonhuman Primates	248
8.3.2 CYP2D in Rat	249
8.3.3 CYP2D in Mouse	250

8.3.4	CYP2D in Other Species	251
8.4	Hepatic and Extrahepatic Expression of CYP2D Enzymes	252
8.4.1	Ontogeny, Induction and Regulation	252
8.4.2	Extrahepatic Expression and its Significance	253
8.5	Pharmacogenetics of Human <i>CYP2D6</i>	255
8.5.1	Definition and Determination of CYP2D6 Phenotype	255
8.5.2	Genetic Polymorphism and Interethnic Variation	258
8.5.3	<i>CYP2D6</i> Genotyping	262
8.5.4	Clinical Relevance of CYP2D6 Pharmacogenetics	262
	Acknowledgement	264
	References	264

Chapter 9 The CYP2E Subfamily

Lowell C. Overton, Alice Hudder and Raymond F. Novak

9.1	Introduction	277
9.2	CYP2E1 Tissue and Species Distribution	278
9.3	Age and Gender Differences in Expression	279
9.4	Role in Xenobiotic Metabolism and Toxicity	279
9.5	Substrate Specificity	282
9.6	Regulation by Endogenous and Exogenous Factors	282
9.6.1	Cytokine Regulation of CYP2E1 Expression	282
9.6.2	Hormonal Regulation of CYP2E1 Expression	283
9.6.3	Xenobiotic Regulation of CYP2E1 Gene Expression	291
9.6.4	Metabolic Conditions, Disease States and Oxidative Stress Alter CYP2E1 Expression	295
9.7	Pharmacogenetics and SNPs	297
9.8	Ontogenic Expression	300
	References	301

Chapter 10 The CYP2F, CYP2G and CYP2J Subfamilies

Qing-Yu Zhang and Xinxin Ding

10.1	CYP2F	310
10.1.1	Introduction	310
10.1.2	Human CYP2F1	310
10.1.3	Mouse CYP2F2	314
10.1.4	Goat CYP2F3	318
10.1.5	Rat CYP2F4	319
10.1.6	CYP2F in Other Species	320
10.1.7	Perspective	320
10.2	CYP2G1	321

10.2.1	Introduction	321
10.2.2	Rabbit CYP2G1	322
10.2.3	Rat CYP2G1	325
10.2.4	Mouse CYP2G1	326
10.2.5	Human CYP2G	330
10.2.6	CYP2G in Other Species	330
10.2.7	Perspective	331
10.3	CYP2J	332
10.3.1	Introduction	332
10.3.2	Rabbit CYP2J	333
10.3.3	Rat CYP2J	333
10.3.4	Mouse CYP2J	337
10.3.5	Human CYP2J2	339
10.3.6	CYP2J in Other Species	343
10.3.7	Perspective	344
	Acknowledgments	344
	References	344

Chapter 11 The CYP3 Family

David J. Greenblatt, Ping He, Lisa L. von Moltke and Michael H. Court

11.1	Introduction	354
11.2	Pharmacogenomics	357
11.3	Enzyme Kinetics of CYP3A	360
11.4	Individual Variability in CYP3A Metabolic Phenotype	361
11.5	Age and Gender Effects on CYP3A Phenotype	363
11.5.1	<i>In vitro</i> and Experimental Studies	363
11.5.2	Clinical Studies	364
11.6	Drug Interactions with CYP3A Substrates	365
11.6.1	Drug Interactions via Metabolic Inhibition	365
11.6.2	Drug Interactions Involving Metabolic Induction	371
11.7	Comment	372
	Acknowledgements	372
	References	372

Chapter 12 The CYP4 Family

Allan E. Rettie and Edward J. Kelly

12.1	Introduction	385
12.2	CYP4A	386
12.2.1	Multiplicity	386
12.2.2	Tissue Distribution	387
12.2.3	Substrate Specificity	389
12.2.4	Gene Regulation	391

12.2.5	Pharmacogenetics	393
12.3	CYP4B	394
12.3.1	Multiplicity	394
12.3.2	Tissue Distribution	394
12.3.3	Substrate Specificity	395
12.3.4	Gene Regulation	398
12.3.5	Pharmacogenetics	399
12.4	CYP4F	399
12.4.1	Multiplicity	399
12.4.2	Tissue Distribution	399
12.4.3	Substrate Specificity	400
12.4.4	Gene Regulation	404
12.4.5	Pharmacogenetics	405
12.5	'Orphan' CYP4 Enzymes	405
12.5.1	CYP4X	406
12.5.2	CYP4Z	406
12.5.3	CYP4V	406
12.6	Concluding Remarks	407
	Acknowledgements	407
	References	407

Part C

Chapter 13 Receptor-Mediated Regulation of Cytochromes P450

Kouichi Yoshinari, Eric Tien, Masahiko Negishi and Paavo Honkakoski

13.1	Introduction	418
13.2	Activation Mechanisms	419
13.3	Ligand-Dependent Mechanism	419
13.3.1	Ligand Binding and Activation by PXR	419
13.3.2	Ligand Binding and Activation by CAR	421
13.4	Signal-Dependent Activation	423
13.4.1	CAR De-phosphorylation and PP2A	423
13.4.2	AMP-Activated Protein Kinase (AMPK)	424
13.4.3	PKC and PKA	425
13.4.4	Glucocorticoid	425
13.4.5	Fatty Acids	426
13.4.6	Retinoic Acids	426
13.4.7	Pancreatic Hormones and Starvation	426
13.4.8	Growth Factors and MEK-ERK	428
13.4.9	Inflammation and NF- κ B	428
13.5	CYP Subfamilies 2-4 Under Regulation by CAR and PXR	428
13.5.1	CYP2A	429
13.5.2	CYP2B	430
13.5.3	CYP2C	431

13.5.4	CYP2E1	432
13.5.5	CYP3A	432
13.5.6	CYP4A	434
13.6	Other Nuclear Receptors Regulate Members of the CYP2 and CYP3 Family	434
13.6.1	HNF-4	434
13.6.2	PPAR α	435
13.6.3	VDR	435
13.6.4	FXR	435
13.6.5	LXR	436
13.7	Other CYPs Influenced by CAR, PXR and Their Activators	436
13.8	Perspective	437
13.8.1	Mechanism of Ligand-Elicited Activation	438
13.8.2	Direct Targets of Signal-Mediated Activation	438
13.8.3	Finding the PB Receptor	438
13.8.4	Diverse Roles in Regulating Liver Function and Disease	439
	References	439

Chapter 14 Modulation of Cytochromes P450 by Phytochemicals

Michael Murray

14.1	Introduction	450
14.1.1	Background to the Effects of Phytochemicals on CYP Enzymes	450
14.1.2	Mechanisms of CYP Inhibition	451
14.1.3	Altered Regulation of CYP Genes	451
14.2	Polyphenols	452
14.2.1	Effects of Polyphenols on the Activation of Genotoxic Chemicals by CYPs	453
14.3	Methylenedioxyphenyl Compounds	461
14.3.1	Role of CYPs in the Formation of Inhibitory Metabolites of MDP Compounds	461
14.3.2	Induction of CYPs by MDP Compounds	464
14.4	Furanocoumarins (Psoralens)	464
14.4.1	Anticarcinogen and Drug-Interaction Effects Mediated by CYP Inhibition	464
14.5	Carotene and Related Plant Pigments	465
14.5.1	Anticarcinogenic Effects Mediated by Altered CYP Regulation	465
14.6	Sulphur and Indole-Containing Compounds in Cruciferous Vegetables	469
14.6.1	Inhibitory Effects on CYP Enzymes	469
14.6.2	CYP Induction by Indoles and Isothiocyanates	470

14.7	Other Phytochemicals	471
14.7.1	Induction of CYPs by Complex Terpenoids and Related Agents	471
14.7.2	Inhibition of CYPs by Terpenoids and Role of CYPs in Terpenoid Oxidation	471
14.8	Summary and Future Issues	472
	Acknowledgements	473
	References	473

Chapter 15 Cytochromes P450 in Cancer Therapeutics

Thomas K.H. Chang

15.1	Introduction	481
15.2	Human Cytochromes P450 as Catalysts of Anticancer Drug Metabolism	482
15.2.1	Anticancer Prodrugs Bioactivated by Cytochromes P450	482
15.3	Drug-Metabolising Cytochrome P450 Enzyme Expression in Human Tumours	488
15.3.1	Tumoural Drug Metabolism	491
15.3.2	Cytochrome P450 and Resistance to Cancer Chemotherapy	491
15.4	Cytochrome P450 Gene-Directed Enzyme Prodrug Therapy (GDEPT)	492
15.4.1	Oxazaphosphorine Anticancer Prodrug in Combination with a Cytochrome P450 Gene	492
15.4.2	Clinical Trials of Oxazaphosphorine Anticancer Prodrugs and Cytochrome P450-Based GDEPT	495
15.4.3	Experimental Anticancer Prodrug in Combination with a Cytochrome P450 Gene	495
15.4.4	Other Potential Drug/Gene Combinations in Cytochrome P450-Based GDEPT	496
15.5	Other Cytochrome P450-Based Experimental Approaches to Cancer Chemotherapy	497
15.5.1	Novel Cytochrome P450-Activated Prodrugs	497
15.5.2	Cytochrome P450 and Cancer Immunotherapy	498
15.5.3	Cytochrome P450-Based Antisense Oligomers	498
15.5.4	Small Molecule Inhibitors of Cytochrome P450	498
15.6	Conclusions	499
	Acknowledgements	499
	References	499